IP Library › Granted Patent US 11,707,457
Granted Patent B2
US 11,707,457 · App. 18/045,394 · Granted Jul 25, 2023

IRAK degraders and uses thereof

Inventor: Matthew M. Weiss (Boston, MA)
Assignee: Kymera Therapeutics, Inc.
A61K31/4545A61K31/4725A61K31/497A61K31/501A61K31/506A61K31/519A61P35/00C07D417/14C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,707,457
App. No.
18/045,394
Granted
Jul 25, 2023
Kind
B2
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Claims (60)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

27. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

28. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

29. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

30. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2023
From: WEISS, MATTHEW M.
To: KYMERA THERAPEUTICS, INC.
Reel/Frame 062257/0581 →
Continuity (4)
Continuation 17125426 · Dec 17, 2020
Provisional Application 63040906 · Jun 18, 2020
Provisional Application 62949298 · Dec 17, 2019
Related Publication 20230144292A1 · May 11, 2023
Cited By (8)
US 12,187,744 US 12,258,341 US 12,497,402 US 12,539,295 US 12,545,659 US 12,551,564 US 12,558,427 US 12,655,159